Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: A meta-analysis of the liraglutide clinical trial programme
Aim: Effective type 2 diabetes management requires a multifactorial approach extending beyond glycaemic control. Clinical practice guidelines suggest targets for HbA1c, blood pressure and lipids, and emphasize weight reduction and avoiding hypoglycaemia. The phase 3 clinical trial programme for lira...
Prif Awduron: | Zinman, B, Schmidt, W, Moses, A, Lund, N, Gough, S |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
2012
|
Eitemau Tebyg
-
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme.
gan: Zinman, B, et al.
Cyhoeddwyd: (2012) -
Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
gan: Schmidt, W, et al.
Cyhoeddwyd: (2009) -
Liraglutide Is Associated with Reduced Rates of Hypoglycemic Events Versus Glimepiride When Achieving Target HbA(1c)
gan: Gough, S, et al.
Cyhoeddwyd: (2010) -
Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin
gan: Zinman, B, et al.
Cyhoeddwyd: (2011) -
Continuation of Liraglutide during Fasting is not Associated with Hypoglycaemia
gan: Rosalie Koot, et al.
Cyhoeddwyd: (2017-10-01)